Philips has now developed a device intended to integrate two forms of laser-based PAD therapy, atherectomy and intravascular ...

Solaris Endovascular today announced its formation to develop solutions for dialysis access and treating peripheral artery ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

Learn about Peripheral Artery Disease (PAD) and its impact on the Black community. Discover the risks, symptoms, and treatment options for this irreversible medical condition.

Johnson & Johnson MedTech's Shockwave Medical unit today announced the first clinical outcomes associated with its Javelin ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular Institute of the South successfully treats first patient in the U.S. using Philips ...

Royal Philips announced enrollment of the first patient in THOR, a United States investigational device exemption (IDE) clinica ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

Netherlands-based diagnostics imaging company Royal Philips announced the enrolment of its first patient in the US THRO IDE ...

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...